{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:06:02Z","timestamp":1787785562561,"version":"build-2784847793"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,3,3]],"date-time":"2015-03-03T00:00:00Z","timestamp":1425340800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s10620-015-3606-z","type":"journal-article","created":{"date-parts":[[2015,3,2]],"date-time":"2015-03-02T08:43:29Z","timestamp":1425285809000},"page":"2119-2129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Adalimumab Therapy Has a Beneficial Effect on Bone Metabolism in Patients with Crohn\u2019s Disease"],"prefix":"10.1007","volume":"60","author":[{"given":"Sundaram G.","family":"Veerappan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard J.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colm A.","family":"O\u2019Morain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline S.","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara M.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,3]]},"reference":[{"key":"3606_CR1","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00004424-197611000-00007","volume":"11","author":"HK Genant","year":"1976","unstructured":"Genant HK, Mall JC, Wagonfeld JB, Horst JV, Lanzi LH. Skeletal demineralization and growth retardation in inflammatory bowel disease. Invest Radiol. 1976;11:541\u2013549.","journal-title":"Invest Radiol"},{"key":"3606_CR2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/gut.40.2.228","volume":"40","author":"I Bjarnasson","year":"1997","unstructured":"Bjarnasson I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut. 1997;40:228\u2013233.","journal-title":"Gut"},{"key":"3606_CR3","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1111\/j.1572-0241.1998.468_q.x","volume":"93","author":"RD Pollak","year":"1998","unstructured":"Pollak RD, Karmeli F, Eilakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol. 1998;93:1483\u20131490.","journal-title":"Am J Gastroenterol"},{"key":"3606_CR4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/gut.2003.026799","volume":"53","author":"T Card","year":"2004","unstructured":"Card T, West J, Hubbard R, Logan RF. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut. 2004;53:251\u2013255.","journal-title":"Gut"},{"key":"3606_CR5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/gut.37.1.71","volume":"37","author":"JA Silvennoinen","year":"1995","unstructured":"Silvennoinen JA, Karttunen TJ, Niemelia SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut. 1995;37:71\u201376.","journal-title":"Gut"},{"key":"3606_CR6","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1046\/j.1365-2036.2002.01363.x","volume":"16","author":"EJ Lamb","year":"2002","unstructured":"Lamb EJ, Wong T, Smith DJ, et al. Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16:1895\u20131902.","journal-title":"Aliment Pharmacol Ther"},{"key":"3606_CR7","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1172\/JCI119333","volume":"99","author":"P Ammann","year":"1997","unstructured":"Ammann P, Rizzoli R, Bonjour JP, et al. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J Clin Invest. 1997;99:1699\u20131703.","journal-title":"J Clin Invest"},{"key":"3606_CR8","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/rheumatology\/38.9.841","volume":"38","author":"P Oelzner","year":"1999","unstructured":"Oelzner P, Franke S, Muller A, Hein G, Stein G. Relationship between soluble markers of immune activation and bone turnover in post-menopausal women with rheumatoid arthritis. Rheumatology (Oxford). 1999;38:841\u2013847.","journal-title":"Rheumatology (Oxford)"},{"key":"3606_CR9","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/gut.32.8.913","volume":"32","author":"SH Murch","year":"1991","unstructured":"Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut. 1991;32:913\u2013917.","journal-title":"Gut"},{"key":"3606_CR10","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/clinchem\/47.7.1297","volume":"47","author":"M Komatsu","year":"2001","unstructured":"Komatsu M, Kobayashi D, Saito K, et al. Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem. 2001;47:1297\u20131301.","journal-title":"Clin Chem"},{"key":"3606_CR11","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/0140-6736(92)90573-L","volume":"339","author":"GA Lanfranchi","year":"1992","unstructured":"Lanfranchi GA, Tragnone A. Serum and faecal tumour necrosis factor-alpha as marker of intestinal inflammation. Lancet. 1992;339:1053.","journal-title":"Lancet"},{"key":"3606_CR12","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1053\/gast.1996.v111.pm8898640","volume":"111","author":"CL Lin","year":"1996","unstructured":"Lin CL, Moniz C, Chambers TJ, Chow JW. Colitis causes bone loss in rats through suppression of bone formation. Gastroenterology. 1996;111:1263\u20131271.","journal-title":"Gastroenterology"},{"key":"3606_CR13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00005176-199703000-00011","volume":"24","author":"JS Hyams","year":"1997","unstructured":"Hyams JS, Wyzga N, Kreutzer DL, Justrinich CJ, Gronowicz GA. Alterations in bone metabolism in children with inflammatory bowel disease: an in vitro study. J Pediatr Gastroenterol Nutr. 1997;24:289\u2013295.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"3606_CR14","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/jcp.1082","volume":"187","author":"S Kumar","year":"2001","unstructured":"Kumar S, Votta BJ, Rieman DJ, Badger AM, Gowen M, Lee JC. IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase. J Cell Physiol. 2001;187:294\u2013303.","journal-title":"J Cell Physiol"},{"key":"3606_CR15","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1359\/jbmr.2002.17.4.695","volume":"17","author":"FA Sylvester","year":"2002","unstructured":"Sylvester FA, Wyzga N, Hyams JS, Gronowicz GA. Effect of Crohn\u2019s disease on bone metabolism in vitro: a role for interleukin-6. J Bone Miner Res. 2002;17:695\u2013702.","journal-title":"J Bone Miner Res"},{"key":"3606_CR16","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2036.2004.02152.x","volume":"20","author":"N Franchimont","year":"2004","unstructured":"Franchimont N, Putzeys V, Collette J, et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn\u2019s disease. Aliment Pharmacol Ther. 2004;20:607\u2013614.","journal-title":"Aliment Pharmacol Ther"},{"key":"3606_CR17","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1365-2036.2004.02097.x","volume":"20","author":"BM Ryan","year":"2004","unstructured":"Ryan BM, Russel MGVM, Schurgers L, et al. Effect of antitumour necrosis factor-\u03b1 therapy on bone turnover in patients with active Crohn\u2019s disease: a prospective study. Aliment Pharmacol Ther. 2004;20:851\u2013857.","journal-title":"Aliment Pharmacol Ther"},{"key":"3606_CR18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/01.mcg.0000190762.80615.d4","volume":"40","author":"MT Abreu","year":"2006","unstructured":"Abreu MT, Geller JL, Vasiliauskas EA, et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn\u2019s disease. J Clin Gastroenterol. 2006;40:55\u201363.","journal-title":"J Clin Gastroenterol"},{"key":"3606_CR19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000091299","volume":"24","author":"P Miheller","year":"2006","unstructured":"Miheller P, Muzes G, Zagoni T, Toth M, Racz K, Tulassay Z. Infliximab therapy improves the bone metabolism in fistulizing Crohn\u2019s disease. Dig Dis. 2006;24:201\u2013206.","journal-title":"Dig Dis"},{"key":"3606_CR20","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/ibd.20234","volume":"13","author":"P Miheller","year":"2007","unstructured":"Miheller P, Muzes G, R\u00e1cz K, et al. Changes of OPG and RANKL concentrations in Crohn\u2019s disease after infliximab therapy. Inflamm Bowel Dis. 2007;13:1379\u20131384.","journal-title":"Inflamm Bowel Dis"},{"key":"3606_CR21","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1196\/annals.1346.055","volume":"1068","author":"M Pazianas","year":"2006","unstructured":"Pazianas M, Rhim AD, Weinberg AM, Su C, Lichtenstein GR. The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn\u2019s disease. Ann N Y Acad Sci. 2006;1068:543\u2013556.","journal-title":"Ann N Y Acad Sci"},{"key":"3606_CR22","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1155\/2007\/216162","volume":"21","author":"M Mauro","year":"2007","unstructured":"Mauro M, Radovic V, Armstrong D. Improvement of lumbar bone mass after infliximab therapy in Crohn\u2019s disease patients. Can J Gastroenterol. 2007;21:637\u2013642.","journal-title":"Can J Gastroenterol"},{"key":"3606_CR23","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1111\/j.1572-0241.2005.50219.x","volume":"100","author":"M Bernstein","year":"2005","unstructured":"Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn\u2019s disease. Am J Gastroenterol. 2005;100:2031\u20132035.","journal-title":"Am J Gastroenterol"},{"key":"3606_CR24","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/rheumatology\/kes320","volume":"52","author":"CL Krieckaert","year":"2013","unstructured":"Krieckaert CL, Nurmohammed MT, Wolbink G, Lems WF. Changes in bone mineral density during long-term treatment with Adalimumab in patients with rheumatoid arthritis: a cohort study. Rheumatology (Oxford). 2013;52:547\u2013553.","journal-title":"Rheumatology (Oxford)"},{"key":"3606_CR25","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/jbmr.5650100203","volume":"10","author":"SA Harris","year":"1995","unstructured":"Harris SA, Enger RJ, Riggs BL, Spelsberg TC. Development and characterization of a conditionally immortalized human fetal osteoblastic cell line. J Bone Miner Res. 1995;10:178\u2013186.","journal-title":"J Bone Miner Res"},{"key":"3606_CR26","unstructured":"Lancaster MV, Fields RD. Antibiotic and cytotoxic drug susceptibility assays using resazurin and poising agents. US Patent No. 5,501,959; 1996."},{"key":"3606_CR27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/01.MIB.0000164015.60795.ca","volume":"11","author":"CN Bernstein","year":"2005","unstructured":"Bernstein CN, Sargent M, Leslie WD. Serum osteoprotegerin is increased in Crohn\u2019s disease: a population-based case control study. Inflamm Bowel Dis. 2005;11:325\u2013330.","journal-title":"Inflamm Bowel Dis"},{"key":"3606_CR28","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/0016-5085(94)90227-5","volume":"107","author":"S Ghosh","year":"1994","unstructured":"Ghosh S, Cowen S, Hannan W, Ferguson A. Low bone mineral density in Crohn\u2019s disease but not in ulcerative colitis at diagnosis. Gastroenterology. 1994;107:1031\u20131039.","journal-title":"Gastroenterology"},{"key":"3606_CR29","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.4049\/jimmunol.159.12.6276","volume":"159","author":"SE Plevy","year":"1997","unstructured":"Plevy SE, Landers CJ, Prehn J, et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn\u2019s disease. J Immunol. 1997;159:6276\u20136282.","journal-title":"J Immunol"},{"key":"3606_CR30","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1053\/gast.2000.16518","volume":"119","author":"KV Haderslev","year":"2000","unstructured":"Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn\u2019s disease. Gastroenterology. 2000;119:639\u2013646.","journal-title":"Gastroenterology"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-015-3606-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-015-3606-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-015-3606-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T14:37:32Z","timestamp":1691505452000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-015-3606-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,3]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["3606"],"URL":"https:\/\/doi.org\/10.1007\/s10620-015-3606-z","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,3]]}}}